Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape

  • Salguero-Aranda, Carmen
  • Amaral, Ana Teresa
  • Olmedo-Pelayo, Joaquín
  • Díaz-Martín, J.
  • Álava, Enrique de
© 2020 by the authors., Ewing sarcoma is a highly aggressive round cell mesenchymal neoplasm, most often occurring in children and young adults. At the molecular level, it is characterized by the presence of recurrent chromosomal translocations. In the last years, next-generation technologies have contributed to a more accurate diagnosis and a refined classification. Moreover, the application of these novel technologies has highlighted the relevance of intertumoral and intratumoral molecular heterogeneity and secondary genetic alterations. Furthermore, they have shown evidence that genomic features can change as the tumor disseminates and are influenced by treatment as well. Similarly, next-generation technologies applied to liquid biopsies will significantly impact patient management by allowing the early detection of relapse and monitoring response to treatment. Finally, the use of these novel technologies has provided data of great value in order to discover new druggable pathways. Thus, this review provides concise updates on the latest progress of these breakthrough technologies, underscoring their importance in the generation of key knowledge, prognosis, and potential treatment of Ewing Sarcoma., This work was supported by grants from the Consejería de Salud (Junta de Andalucía, grants No PI-0036-2017 and PI-0040-2017) awarded to JDM and ATA, respectively; by grants from the Asociación Pablo Ugarte, Fundación María García Estrada and FARO niños con cáncer to JDM and EdA. EdA’s laboratory is supported by the AECC project (GCB13-1578), ISCIIIFEDER (PI14/01466, PI17/00464), CIBERONC (CB16/12/00361) and Fundación CRIS Contra el Cáncer. This work was also supported by a Juan de la Cierva Incorporación fellowship (IJC-2018-036767-I) to ATA, and a pre-doctoral fellowship from the VI Plan Propio from the Universidad de Sevilla to JOP.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma

  • Salguero-Aranda, Carmen
  • Olmedo-Pelayo, Joaquín
  • Álava, Enrique de
  • Amaral, Ana Teresa
  • Díaz-Martín, J.
The Hippo pathway is an evolutionarily conserved modulator of developmental biology with a key role in tissue and organ size regulation under homeostatic conditions. Like other signaling pathways with a significant role in embryonic development, the deregulation of Hippo signaling contributes to oncogenesis. Central to the Hippo pathway is a conserved cascade of adaptor proteins and inhibitory kinases that converge and regulate the activity of the oncoproteins YAP and TAZ, the final transducers of the pathway. Elevated levels and aberrant activation of YAP and TAZ have been described in many cancers. Though most of the studies describe their pervasive activation in epithelial neoplasms, there is increasing evidence pointing out its relevance in mesenchymal malignancies as well. Interestingly, somatic or germline mutations in genes of the Hippo pathway are scarce compared to other signaling pathways that are frequently disrupted in cancer. However, in the case of sarcomas, several examples of genetic alteration of Hippo members, including gene fusions, have been described during the last few years. Here, we review the current knowledge of Hippo pathway implication in sarcoma, describing mechanistic hints recently reported in specific histological entities and how these alterations represent an opportunity for targeted therapy in this heterogeneous group of neoplasm., E.d.Á.’s laboratory is supported by ISCIIIFEDER (PI20/00003) to E.d.Á., Consejería de Salud y Familias, Junta de Andalucía (PE-0186-2018) to E.d.Á. and (PI-0061-2020) to C.S.-A. and E.d.Á., GEIS (Beca José María Buesa) to A.T.A., GEIS-Fundación Mari Paz Jiménez Casado (Beca Trienal a la Investigación en Sarcomas) to J.D.-M., Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada and CIBERONC. C.S.-A. is supported by the European Social Fund and the Junta de Andalucía (Talento Doctores 2020, DOC_01473), J.O.-P. is granted by a pre-doctoral fellowship from the VI Plan Propio from the Universidad de Sevilla; A.T.A. is supported Juan de la Cierva Incorporación fellowship (IJC-2018-036767-I), and J.D.-M. is supported by CIBERONC (CB16/12/00361)., Peer reviewed